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A B S T R A C T
Background: Human experimental malaria infections have
been safely carried out previously. The objective of this
study was to evaluate infection rates and clinical safety of
different protocols for human experimental malaria induced
by Plasmodium falciparum-infected mosquitoes.
Methods: Thirty nonimmune volunteers were infected by
bites of 1-2 or 4-7 Anopheles stephensi mosquitoes infected
with the NF54 strain of P. falciparum.
Results: A 100 or 50% infection rate was obtained after
bites of 4-7 and 1-2 infected mosquitoes, respectively.
Median prepatent period was 8.8 days. The most common
symptoms after a median incubation time of eight days
were headache, malaise/fatigue and fever. There was no
significant difference in clinical and parasitological presen-
tation between groups infected by 4-7 or 1-2 mosquitoes.
Delay of treatment by maximally 48 hours after the first
positive thick smear was generally well tolerated but fever
was higher and more frequently observed. The most prom-
inent laboratory abnormality was uncomplicated thrombo-
cytopenia. Two volunteers with parasitaemia developed
psychiatric side effects after chloroquine treatment.
Conclusion: With stringent inclusion criteria, close
monitoring and immediate administration of treatment
upon detection of parasitaemia, experimental human
malaria challenges can be considered safe and generally
well tolerated.
I N T R O D U C T I O N
Malaria is one of the most important infectious diseases
worldwide. The number of infected people is increasing
due to human migration, climate changes, failure of
programmes for malaria control and the global spread of
drug resistance. Today, malaria is found throughout the
tropical and subtropical regions of the world and causes
more than 300 million acute illnesses and at least one
million deaths annually.1 The potential effect of vaccines
on the devastating malaria situation worldwide justifies
the highest priority for its development. Pre-erythrocytic
vaccines are partly developed to prevent disease in people
travelling to malaria-endemic countries and for children
in endemic countries. Asexual vaccines, which contain
blood stage antigens, are developed to reduce the severity
and lethality of malaria in endemic countries.2 Preclinical
studies have proven to be useful to test malaria vaccine
candidates, but the ultimate validation of efficacy depends
on human studies.3 Due to limited resources, only the
most promising vaccines can be tested in elaborate field
trials in endemic areas. In addition, human challenges
have shown to be safe, reliable and ethically acceptable
for testing the efficacy of potential malaria vaccines.4
Hundreds of volunteers have been experimentally infected
by bites of generally five infected mosquitoes.4-8
The objective of this study was to evaluate infection rates
and clinical safety of different protocols for human experi-
mental malaria induced by Plasmodium falciparum-infected
mosquitoes.
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M A T E R I A L S  A N D  M E T H O D S
Production of infected mosquitoes
Culture of P. falciparum parasites and the infection of
Anopheles stephensi mosquitoes has been a routine proced-
ure for the past ten years.9 The chloroquine-sensitive NF
54 strain was used in all challenge studies. Batches with
more than 90% infected Anopheles stephensi mosquitoes
were used with a mean of at least 10,000 sporozoites per
paired salivary gland. A small cage containing the desired
number of mosquitoes was placed between the forearms
and the mosquitoes were allowed to feed for ten minutes.
Blood engorged mosquitoes were dissected to confirm the
presence of sporozoites in the salivary glands. If this was
not the case, another feeding session followed (maximum
of three) until the desired number of infected mosquitoes
had fed.
Recruitment
Thirty healthy volunteers (18 to 45 years) were included.
Exclusion criteria were 1) previous history of malaria or
travel to malaria endemic areas, 2) previous history of
dermatological, central nervous system, renal, cardiac,
pulmonary, hepatic, and splenetic disease, splenectomy,
pregnancy and lactation, 3) need for medication, and 4)
known allergy to antimalarial agents. Volunteers were
recruited through general advertisements in public places
and local journals. All volunteers had to live in the vicinity
of our hospital. Screening included a physical examination,
complete blood count, liver and renal function tests, urin-
alysis for glucosuria, protenuria and pregnancy test, and
serological testing for antimalarial antibodies, HIV, and
hepatitis B and C. The protocol was adapted to more
stringent criteria of <10% for risk of coronary heart disease.
Risk was calculated according to the Framingham Heart
Study Coronary Heart Disease Risk Prediction Chart.10
The volunteers were informed about the expected adverse
events and risks before inclusion. An informed consent
form was signed by all subjects. An independent specialist
in internal medicine could be consulted by the subjects to
obtain information on the studies. The subjects’ general
practitioners were asked to mention any conditions known
to them that could increase the risk of an adverse outcome.
The studies were approved by the institutional ethical board
(CWOM numbers 0004-0090, 0011-0262, 2001/203,
and 2002/170).
Experimental set-up
The studies were conducted from 1999 to 2003 at the
Centre for Clinical Malaria Studies in the Radboud
University Medical Centre, Nijmegen, the Netherlands.
In Group A, 15 (three groups of five) volunteers were chal-
lenged by bites of 4-7 infected mosquitoes. Thick smears
were taken following the World Health Organisation’s
standard procedure. Smears were screened for parasites in
200 fields at high-power magnification. Standard chloro-
quine (base 100 mg, salt 136.3 mg, Aventis) treatment,
10 mg/kg initially followed by 5 mg/kg after 6, 24 and
48 hours, was started immediately after detection of para-
sitaemia by thick smear.
In group B (5 volunteers), curative treatment was delayed
for maximally 48 hours after the first microscopic detection
of parasitaemia, to monitor parasite multiplication. To
ensure maximal safety, we admitted the volunteers to the
hospital as soon as the thick smear was positive. They
were closely monitored with review by a physician unrelated
to the study. Treatment was immediately initiated when
parasitaemia was >500/l, in case of severe laboratory
abnormalities, or on development of clinical symptoms
that required prompt treatment according to either the
investigator, the independent physician, or the volunteer.
In Group C, ten (two groups of five) volunteers were
challenged by bites of 1-2 infected mosquitoes.
Follow-up
Follow-up of volunteers in group A and C was on an out-
patient basis with close monitoring. Ear temperature was
measured, and all symptoms were recorded on a case report
form at every visit. Volunteers were requested to measure
their temperature twice daily, and note their symptoms in
a booklet. At the end of the study the subjects were asked
to complete a questionnaire on their perception on in-
conveniences and severity of disease during the study.
Thick smears were done twice daily from day 6 after
infection until they were positive and treatment had been
initiated. Chloroquine treatment was provided to all vol-
unteers including the ones whose thick smears remained
negative to the end of the study. Standard blood and urine
laboratory tests were done once daily in the three days post-
treatment including haemoglobin, platelet count, white
blood cell count with differentiation, creatinine, blood urea
nitrogen, sodium, potassium, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), total bilirubin,
alkaline phosphatase, lactic dehydrogenase, gamma glutamyl
transpeptidase and blood glucose. Urine analysis included
protein and glucose measurement. Thick smears were
carried out daily until two negatives had been obtained for
P. falciparum. At the end of the study (ten days after first
detection of parasitaemia) blood was drawn for standard
clinical laboratory tests and a control thick smear.
Data analysis
All available data were analysed in SPSS 10.0 for Windows.
Data of three volunteers were excluded from clinical and
laboratory analysis, because of the development of concur-
rent illnesses (influenza A, flu-like syndrome, and myocar-
dial infarction). Prepatent period was defined as the period
of time between the challenge and microscopic detection
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of parasites; incubation period was defined as time from
the challenge until the first fever episode (>38°C). If fever
did not occur, incubation time was regarded as missing.
Duration of symptoms was defined as the number of days
with malaria or chloroquine-related symptoms. Parasite
densities were compared after transformation (ln). Clinical
differences between group B, group C and reference
group A were tested using the nonparametric Wilcoxon’s
rank-sum test for continuous variables and the Fisher’s
exact test for dichotomous variables. Thrombocytopenia
was defined as a platelet count below 120 x 109/l. Changes
in blood cell counts were tested by the nonparametric
Friedman’s rank test.
R E S U L T S
Infection by 4-7 mosquitoes
Group A of 15 subjects consisted of five males, 13 Cauca-
sians, one Asian and one Black. All volunteers developed
parasitaemia after bites of 4-7 infected mosquitoes and
were immediately treated with chloroquine. Results of
two volunteers were excluded from the analysis because
of concurrent illnesses (influenza A and flu-like syndrome).
The median prepatent period was 8.8 days (table 1).
Geometric mean of maximum parasite density was 39.9
parasites/l. The median incubation period was eight days
while median duration of symptoms was six days (from 4
to 122 days after infection). Of the volunteers, 46% (6/13)
developed fever, of which 67% in the prepatent period.
Altogether, 93% (12/13) of the volunteers showed signs
and symptoms one to four days before detection of para-
sitaemia.
All volunteers in group A developed a mild, uncompli-
cated episode of clinical malaria. The most common symp-
toms were headache, malaise and/or fatigue, and myalgia
and/or arthralgia (table 2).
White blood cell (WBC) count was decreased on the day
the thick smear became positive (day 0, figure 1A) with a
nadir at day 2 and recovery to baseline levels by day 10.
Thrombocytopenia (<120 x 109/l) occurred in three of the
13 (23%) volunteers. Platelet counts (figure 1B) also showed
a pattern of significant decline and recovery with a nadir at
days 1 to 3. Lymphocyte counts (figure 1C) also decreased,
but recovered somewhat sooner. Absolute neutrophil counts
did not change significantly (data not shown, Friedman
rank test: 2 = 11.2; df = 6; p=0.08).
Chloroquine treatment was generally uneventful but two
volunteers developed side effects. One female became
depressed but recovered completely within five days. A
second female suffered from paranoia, depersonalisation,
nightmares, and concentration problems. There was no
medical or family history of neuro-psychiatric disease.
Symptoms started on the second day after the start of
chloroquine treatment (a total dose of 1.5 g, 27.3 mg/kg).
Most symptoms subsided within five days, but the con-
centration problems took 122 days to resolve.
Infection by 4-7 mosquitoes with delay of treatment
All five volunteers developed signs and symptoms of mild
malaria (table 1). Clinical presentation of group B was
similar to group A, but there was a tendency towards
higher fever frequencies with higher maximum tempera-
tures (tables 1 and 2). All volunteers developed thrombo-
cytopenia. One volunteer had to be treated with chloroquine
after 41.5 hours because of a platelet count of 15 x 109/l,
without symptoms of bleeding. This was a single obser-
vation in a series of measurements showing a gradual
decline from 248 to 127 x 109/l in four days, followed by
a sudden drop to 15 x 109/l and a recovery to 120 x 109/l
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Table 1
Clinical responses to experimentally induced P. falciparum malaria
A B C
NUMBER OF MOSQUITOES 4-7 4-7 1-2
NUMBER OF VOLUNTEERS 13 5 5
ONSET OF TREATMENT AFTER FIRST POSITIVE DELAYED 48 HOURS AFTER FIRST POSITIVE
THICK SMEAR THICK SMEAR
Prepatent period (days) 8.8 (7.3-10.3) 9.0 (8.0-13.0)
Incubation period (days) 8 (7-11)$ 8 (4-11)
Duration of parasitaemia (days) 2 (1-2) 3 (3-5)* 2 (1-3)
Duration of symptoms (days) 6 (2-122)# 5 (3-6) 5 (1-7)
Highest parasite density (GM#, per/l) 39.9 (23-55) 9.6 (32-124) 38.8 (32-55)
Highest temperature (°C) 37.8 (37.0-39.9) 39.4 (38.0-40.2)** 38.0 (37.3-39.8)
All values are median (range), except # = geometric mean (range); $6/13 volunteers did not develop fever, see table 2; #due to chloroquine-induced psychiatric side
effects; *difference between group A and B, Wilcoxon’s rank sum p=0.001; **difference between group A and B, Wilcoxon’s rank sum p=0.05 (borderline significance).
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Figure 1
Haematological changes after infection with P. falciparum
malaria
The influence of infection on white blood cell (1A), platelet (1B) and
absolute lymphocyte count (1C) were visualised by plotting the median
of all infected volunteers (n=16-21), after subtracting the values on the
day of inclusion (=0 on the y-axis). 
Day 0 on the x-axis indicates the first thick smear positive day.
Differences were tested using Friedman’s rank test. The error bars
indicate the interquartile range (IQR). Figure 1A
White blood cell count (WBC)
(Friedman rank: 2 = 24.2, df = 6, p<0.001)
Range on the day of inclusion: 4.0- 9.6 x 109/l.
Figure 1C
Absolute lymphocyte count (ALC)
(Friedman’s rank: 2 = 63.6; df = 6; p<0.001)
Range on the day of inclusion: 1.2- 3.7 x 109/l.
Figure 1B
Platelet count
(Friedman’s rank: 2 = 67.4; df = 6; p<0.001).
Range on the day of inclusion: 187- 443 x 109/l.
Table 2
Frequency of signs and symptoms in experimentally induced P. falciparum malaria
A B C
NUMBER OF MOSQUITOES 4-7 4-7 1-2
NUMBER OF VOLUNTEERS 13 5 5
ONSET OF TREATMENT AFTER FIRST POSITIVE DELAYED 48 HOURS AFTER FIRST POSITIVE
THICK SMEAR THICK SMEAR
Fever 6 (46.2)* 5 (100) 4 (80)
Headache 12 (92.3) 5 (100) 5 (100)
Malaise and/or fatigue 12 (92.3) 4 (80) 5 (100)
Myalgia and/or arthralgia 9 (69.2) 2 (40) 2 (40)
Nausea with/without vomiting 5 (38.5) 2 (40) 3 (60)
Chills 3 (23.1) 1 (20) 3 (60)
Diarrhoea 2 (15.4) 1 (20) 0
Abdominal pain 2 (15.4) 0 1 (20)
Psychiatric symptoms after onset of 2 (15.4) 0 0
chloroquine treatment
Thrombocytopenia# 3 (23.1) 5 (100)§ 0
*Number of volunteers (%); #<120 x 109/l; §thrombocytopenia occurred in the period of treatment delay.
within nine hours. An inaccurate reading is most likely
in this case. Severity of the thrombocytopenia correlated
with parasite density (Pearson’s correlation coefficient
-0.51, p=0.02). As expected, duration of and maximum
parasitaemias were higher than group A (Wilcoxon’s rank
sum, p=0.001).
Infection by 1-2 mosquitoes
A total of ten volunteers (group C) were exposed to bites of
1-2 infected mosquitoes; five of these ten subjects developed
parasitaemia. Parasitaemia and symptoms were similar to
volunteers infected with 4-7 mosquitoes (tables 1 and 2).
None of the volunteers developed thrombocytopenia. No
significant differences in laboratory results were observed
(data not shown). Volunteers recovered uneventfully from
the malaria episode after chloroquine treatment. The five
volunteers who remained negative were excluded from data
analysis. One of the negative volunteers had an unexpected
event during the study. One day after chloroquine treat-
ment, he developed signs of a myocardial infarction. An
infero-posterior infarction with a significant stenosis in
the circumflex coronary artery was diagnosed. He was
transferred to the Cardiology Department and recovered.
Volunteer perception
On the last follow-up visit, we retrospectively evaluated the
volunteers’ own perceptions on inconveniences and severity
of disease through questionnaires. In group A, burden of
disease was considered to be severe by 54%, and mild by
46% of the volunteers. Of the volunteers of group B 20%
experienced the disease episode as severe, and 80% as
mild. Disease perception was comparable in group C:
20% experienced severe disease and 80% mild. Median
duration of perceived illness was longer in group A and
B, compared with group C (3.0 vs 2.0 days). Volunteers
perceived headache (37%), malaise/fatigue (19%), and fever/
flu-like feeling (15%) as the most unpleasant symptoms.
Of the volunteers, 35% considered disease severity higher
than anticipated, but 78% of volunteers would participate
again.
D I S C U S S I O N
A 100 and 50% infection rate was obtained in 20 and 10
volunteers, respectively, who were experimentally infected
by 4-7 and 1-2 Anopheles stephensi mosquitoes carrying
P. falciparum parasites. It has been reported that at least
five infected mosquitoes should be used to ensure 100%
infection rate, because lower numbers of mosquitoes result
in inconsistent infection rates.6-8 Exposure to 1-2 infected
mosquitoes induced parasitaemia in only five out of ten
volunteers, which corroborates previous findings.11
There are ethical aspects to an infection-inducing challenge
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experiment, which should be evaluated. Such experiments
should not pose risks of irreversible harm if they are con-
fined to self-limiting and completely curable diseases. The
expected risks and discomforts for volunteers should be
taken into account before the assessment of the study’s
scientific rationale.12 In a prospective study, ambulatory
management of imported malaria is safe.13 Follow-up of
our volunteers was in principle on an outpatient basis with
intensive monitoring, which proved to be satisfactory.
Volunteers with an uncomplicated course were only
admitted for observation if chloroquine treatment was
delayed for 48 hours (group B). The risk of complications
was considered to be minimal because of close monitoring
and a low threshold for intervention at this low density of
parasitaemia. Volunteers participating in other studies had
been allowed to develop parasitaemias >105 parasites/l
before treatment was initiated.5,14
Our protocol with delayed treatment was used for a more
precise measure of parasite multiplication. A statistical
model was developed that can provide detailed estimates
of parasite growth rates and may substantially improve the
capacity to evaluate asexual vaccines.15 In addition, treatment
delay provides a possibility to collect data on the initial
immune responses during a malaria episode with possi-
bilities to study immune correlates of protection and
susceptibility to malaria. All five volunteers in group B
developed uncomplicated malaria with a mild increase in
severity of symptoms compared with the group that was
immediately treated when the thick smear was positive. 
Thrombocytopenia was present in all volunteers of group
B, but one single platelet count of 15 x 109/l was obtained
in one individual. This measurement, however, is likely to
be incorrect because values directly before and after were
similar within a nine-hour period of time. In group A
(immediate treatment) 23% (3/13) of the volunteers devel-
oped thrombocytopenia (<120 x 109/l), while 100% (5/5)
developed a low platelet count in group B (delayed treat-
ment). Church et al. found thrombocytopenia (<100 x 109/l)
in ten of 83 (12%) volunteers compared with four of 27
(15%) in our entire study group.4 A correlation between
severity of thrombocytopenia and parasite density has been
reported in 89 cases of acute and imported malaria.15
Nonetheless, this event stresses the need to stay alert and
perform frequent tests. The significant decrease in WBC,
in particular lymphocytes, is consistent with previous
studies.4,16 It has been speculated that redistribution of
lymphocytes into body compartments and apoptosis of T
cells occur in parallel during malaria attacks.17-19
The clinical response to all challenges, i.e. duration of para-
sitaemia, and geometric mean parasitaemia corroborates
previous studies.4-8,14 However, our studies show shorter
prepatent periods, which may be due to differences in
parasite strain (as has been shown before) or different
protocols of laboratory diagnosis.4,11 The number of sporo-
zoites released from the mosquitoes may vary, or a higher
efficiency of liver stage development may be obtained
with some strains. A weak inverse relationship was found
between prepatent period and number of mosquitoes (data
not shown, Pearson’s correlation coefficient: -0.397, p=0.04).
Previous studies have shown inverse correlations between
the estimated inoculum dose and prepatent period.8
Our study shows that incubation time is often shorter than
the prepatent period, which is in contrast to other challenge
studies.6-8,11 Incubation period has been previously reported
from six to 32 days. It is, however, difficult to compare
results from various studies, due to different monitoring
of volunteers and definitions of incubation time.
Clinical symptoms are comparable with previous studies,
but headache was more frequently reported by our volun-
teers.4 A relation between parasite inoculum and severity
of disease has been suggested.20 Challenging with 1-2
mosquitoes does not decrease the symptoms, although
disease perception is less severe.
Unexpected side effects occurred in three volunteers
after the onset of chloroquine treatment. Two volunteers
developed reversible psychiatric symptoms following
treatment (Telgt, et al. in press). Psychiatric side effects
following therapeutic doses of chloroquine have been
reported but are relatively rare.21,22 Symptoms usually
occur when 2 to 6 g of chloroquine is administered, but
both our volunteers received a chloroquine dose below 2
g. For future studies, chloroquine will be replaced by
another antimalarial agent, such as co-arthemeter.
One male volunteer who did not develop parasitaemia had
a myocardial infarction two days after chloroquine adminis-
tration. Cardiac complications during and after adequate
treatment of malaria are extremely rare (0.6%).23,24
Retrospectively, this volunteer appeared to have a moderate
risk of a coronary event within ten years. Volunteers with
a risk of a coronary event greater than 10% will be excluded
in future challenge studies.
In conclusion, P. falciparum (NF54) experimental human
malaria infections with Anopheles stephensi mosquitoes
induced a 100% infection rate after bites of 4-7 infected
mosquitoes and 50% after 1-2 mosquitoes. Using stringent
criteria, including risks for cardiac events, and close
monitoring, with immediate administration of antimalarial
treatment on first detection of parasitaemia, experimental
human malaria challenges can be considered to be safe and
generally well tolerated. In this way, phase IIa challenge
trials can be a powerful tool in the difficult decision-making
process of malaria vaccine development and testing.
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